IL15 and neoplasm: [14–16] IL15-based fusion proteins capable of inhibiting tumour growth were generated, but those products were not able to efficiently localize to tumours at low doses, as a result of an in vivo trapping mechanism.[16, 17] When considering antibodies for tumour targeting applications, the F8 antibody is one of the most promising candidates.